These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 3111138)

  • 1. Pharmacodynamics of [D-Ser (t-Bu)6,Des-Gly10]GnRH ethylamide (Buserelin) in 6 normal volunteers. Its usefulness to monitor treatment of central precocious puberty.
    Reznik Y; Winiger BP; Aubert ML; Sizonenko PC
    Acta Endocrinol (Copenh); 1987 Jun; 115(2):235-42. PubMed ID: 3111138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty.
    Holland FJ; Fishman L; Costigan DC; Luna L; Leeder S
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1065-70. PubMed ID: 3093518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary excretion of [D-Ser(t-Bu)6,Des-Gly10]GnRH ethylamide (buserelin) during therapy of central precocious puberty: a multicentre study.
    Sizonenko PC; Reznik Y; Aubert ML
    Acta Endocrinol (Copenh); 1990 May; 122(5):553-8. PubMed ID: 2112812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal and subcutaneous treatment of central precocious puberty in both sexes with a long-acting analog of luteinizing hormone-releasing hormone.
    Luder AS; Holland FJ; Costigan DC; Jenner MR; Wielgosz G; Fazekas AT
    J Clin Endocrinol Metab; 1984 Jun; 58(6):966-72. PubMed ID: 6427266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subcutaneous and intranasal use of a LH-RH analog in the treatment of girls with central precocious puberty].
    Fideleff HL; Boquete HR; Azaretzky M; Damilano S; Cagide AL; Levalle O
    Medicina (B Aires); 1989; 49(6):567-72. PubMed ID: 2518644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of central precocious puberty with an LHRH analog. Effect on growth and bone maturation after 2 years of treatment].
    Brauner R; Rappaport R
    Arch Fr Pediatr; 1987 Apr; 44(4):271-6. PubMed ID: 3109347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay of an analog of luteinizing hormone-releasing hormone, [D-Ser(tBu)]6des-Gly-NH2(10) ethylamide (Buserelin).
    Saito S; Saito H; Yamasaki R; Hosoi E; Komatsu M; Iwahana H; Maeda T
    J Immunol Methods; 1985 May; 79(2):173-83. PubMed ID: 3923123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men.
    Behre HM; Sandow J; Nieschlag E
    Arzneimittelforschung; 1992 Jan; 42(1):80-4. PubMed ID: 1586387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty.
    Drop SL; Odink RJ; Rouwé C; Otten BJ; Van Maarschalkerweerd MW; Gons M; Bot A; Meradji M; de Jong FH; Slijper FM
    Eur J Pediatr; 1987 May; 146(3):272-8. PubMed ID: 3109919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of central precocious puberty using an intranasal LHRH analogue (buserelin).
    Stanhope R; Adams J; Brook CG
    Clin Endocrinol (Oxf); 1985 Jun; 22(6):795-806. PubMed ID: 3926352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of GnRH analogue (Buserelin) treatment in girls with central precocious puberty.
    Brauner R; Thibaud E; Bischof P; Sizonenko PC; Rappaport R
    Acta Paediatr Scand; 1985 Nov; 74(6):945-9. PubMed ID: 3937430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LH-RH agonistic analog (buserelin) treatment of precocious puberty: collaborative study in Japan.
    Suwa S; Hibi I; Kato K; Nakazima H
    Acta Paediatr Jpn; 1988; 30 Suppl():176-84. PubMed ID: 3146872
    [No Abstract]   [Full Text] [Related]  

  • 14. Final height in sexually precocious girls after therapy with an intranasal analogue of gonadotrophin-releasing hormone (buserelin).
    Stasiowska B; Vannelli S; Benso L
    Horm Res; 1994; 42(3):81-5. PubMed ID: 7995616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins.
    Rime JL; Zumsteg U; Blumberg A; Hadziselimovic F; Girard J; Zurbrügg RP
    Eur J Pediatr; 1988 Apr; 147(3):263-9. PubMed ID: 3134243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH and GHBP activity and not IGF-1 and its receptor activity express growth velocity reduction during treatment of central precocious puberty by a superactive GNRH analogue.
    Eshet R; Silbergeld A; Kauli R; Lazar L; Laron Z
    Isr J Med Sci; 1994 Aug; 30(8):592-5. PubMed ID: 8045738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotrophin responses to GnRH in precocious puberty treated with GnRH analogue.
    Donaldson MD; Stanhope R; Lee TJ; Price DA; Brook CG; Savage DC
    Clin Endocrinol (Oxf); 1984 Nov; 21(5):499-503. PubMed ID: 6437705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model of the distribution and metabolism of the gonadotropin-releasing hormone (GnRH) agonist [D-Trp6,Des-Gly-NH2(10)]GnRH ethylamide in man.
    Candas B; Lacoste D; Normand M; Labrie F
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1046-54. PubMed ID: 2180974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist.
    Tuvemo T; Gustafsson J; Proos LA;
    Horm Res; 2002; 57(1-2):27-31. PubMed ID: 12006716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.